Press release
Tendinopathy Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 5+ Companies are working to improve the Treatment of Space | MiMedx, Hisamitsu Pharmaceuticals, Seikagaku Corporation
Tendinopathy Pipeline
In the Tendinopathy Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Tendinopathy NDA approvals (if any), and product development activities comprising the technology, Tendinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Tendinopathy pipeline treatment landscape of the report, click here @ Tendinopathy Pipeline Outlook- https://www.delveinsight.com/report-store/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Tendinopathy Pipeline Report
• DelveInsight's Tendinopathy Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
• The leading Tendinopathy Companies working in the market include MiMedx, Hisamitsu Pharmaceuticals, Seikagaku Corporation, MetrioPharm, Novartis, TRB Chemedica AG, ZARS Pharma Inc, Zimmer Biomet, Erasmus Medical Center, Merck Sharp & Dohme LLC, Biosplice Therapeutics Inc, Anika Therapeutics Inc, and others
• Promising Tendinopathy Pipeline Therapies in the various stages of development include NGI226, secukinumab, Tendoactive, etoricoxib, diclofenac, SM04755, Saline Injection, Corticosteroid, MRX-7EAT, Dexamethasone Iontophoretic Patch (low dose), and others.
• On July 2023, Novartis Pharmaceuticals announced a study of phase 2 clinical trials for NGI226. The purpose of this study is to measure local and systemic safety and tolerability as well as improvement of Achilles tendon mechanical properties after a single peritendon injection of NGI226 MP in comparison to placebo MP in patients with mid-portion Achilles Tendinopathy.
• On April 2023, Novartis Pharmaceuticals announced a study of phase 3 clinical trials for secukinumab. The purpose of this study is to investigate the efficacy and safety of AIN457 (secukinumab s.c.) compared to placebo in adult patients with moderate to severe rotator cuff Tendinopathy and failure to conventional therapy.
• On January 2023, University of Wisconsin, Madison announced a study of phase 2 clinical trials for PRP and Dry Needling. The overall goal of this research is to find an effective treatment for patellar tendinopathy (PT). To achieve this, we will conduct a double-blinded randomized controlled trial to investigate if platelet-rich plasma is effective for treatment. Clinical (pain and function scores) and bio-mechanical (knee strength) measures will be correlated with disease modification changes assessed using conventional and novel quantitative magnetic resonance imaging (MRI) and ultrasound (US) techniques.
Tendinopathy Overview
Tendinopathies are very common in general population and a huge number of tendon-related procedures take place annually worldwide, with significant socio-economic repercussions. Numerous treatment options are commonly used for tendon disorders.
To explore more information on the latest breakthroughs in the Tendinopathy Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Tendinopathy Emerging Drugs Profile
• dHACM: MiMedx
Tendinopathy Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies Tendinopathy. The Tendinopathy companies which have their Tendinopathy drug candidates in the most advanced stage, i.e phase III include MiMedx.
Request a sample and discover the recent advances in Tendinopathy Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Tendinopathy Drugs and Companies
• NGI226: Novartis Pharmaceuticals
• Tendoactive: Bioiberica
• etoricoxib: Argentine Tennis Association
• diclofenac: Merck Sharp & Dohme LLC
• SM04755: Biosplice Therapeutics Inc
Tendinopathy Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Tendinopathy Therapeutics Market include-
MiMedx, Hisamitsu Pharmaceuticals, Seikagaku Corporation, MetrioPharm, Novartis, TRB Chemedica AG, ZARS Pharma Inc, Zimmer Biomet, Erasmus Medical Center, Merck Sharp & Dohme LLC, Biosplice Therapeutics Inc, Anika Therapeutics Inc, and others.
Dive deep into rich insights for drugs for Tendinopathy Pipeline, click here for Tendinopathy Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Tendinopathy Pipeline Report
• Coverage- Global
• Tendinopathy Companies- MiMedx, Hisamitsu Pharmaceuticals, Seikagaku Corporation, MetrioPharm, Novartis, TRB Chemedica AG, ZARS Pharma Inc, Zimmer Biomet, Erasmus Medical Center, Merck Sharp & Dohme LLC, Biosplice Therapeutics Inc, Anika Therapeutics Inc, and others.
• Tendinopathy Pipeline Therapies- NGI226, secukinumab, Tendoactive, etoricoxib, diclofenac, SM04755, Saline Injection, Corticosteroid, MRX-7EAT, Dexamethasone Iontophoretic Patch (low dose), and others
• Tendinopathy Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Tendinopathy Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Tendinopathy Executive Summary
3. Tendinopathy: Overview
4. Tendinopathy Pipeline Therapeutics
5. Tendinopathy Therapeutic Assessment
6. Tendinopathy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. dHACM: MiMedx
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SI-613: Seikagaku Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Tendinopathy Key Companies
21. Tendinopathy Key Products
22. Tendinopathy- Unmet Needs
23. Tendinopathy- Market Drivers and Barriers
24. Tendinopathy- Future Perspectives and Conclusion
25. Tendinopathy Analyst Views
26. Tendinopathy Key Companies
27. Appendix
Published Important Links-
https://www.storeboard.com/JohnSmith-5965202
https://doodleordie.com/profile/dennydones99
https://macro.market/company/delveinsight-business-research
https://pantip.com/profile/7306022#topics
https://allmylinks.com/dennydonesusa
https://uconnect.ae/read-blog/4382
https://blacksnetwork.net/post/102497_herpetic-keratitis-is-a-condition-that-affects-the-eye-and-is-caused-by-the-herp.html
https://ekonty.com/-dennydones99
https://app.wedonthavetime.org/posts/03e285b9-e449-4c96-b257-8cb7a2b74243
https://www.weddingbee.com/members/dennydones99/
https://community.storytellingwithdata.com/members/me/gallery
https://www.delveinsight.com/report-store/langerhans-cell-histiocytosis-market
https://www.delveinsight.com/report-store/shigellosis-market
https://www.delveinsight.com/report-store/overactive-bladder-market
https://www.delveinsight.com/report-store/somatotropin-deficiency-market
https://www.delveinsight.com/report-store/herpes-zoster-market
https://www.delveinsight.com/report-store/visual-cycle-modulation-vcm-market
https://www.delveinsight.com/report-store/cataract-surgery-complications-market
https://www.delveinsight.com/report-store/vulvovaginal-candidiasis-market
https://www.delveinsight.com/report-store/erosive-hand-osteoarthritis-market
https://www.delveinsight.com/report-store/tissue-heart-valves-cardiovascular-prosthetic-devices-market
https://www.delveinsight.com/report-store/herpetic-keratitis-market-size
https://www.delveinsight.com/report-store/hot-flashes-in-prostate-cancer-market
https://www.delveinsight.com/report-store/alcoholic-hepatitis-market
https://www.delveinsight.com/report-store/thrombotic-thrombocytopenic-purpura-market
https://www.delveinsight.com/report-store/renal-tubular-acidosis-market
https://www.delveinsight.com/report-store/prostate-cancer-market-insight
https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-market
https://www.delveinsight.com/report-store/hyperphosphatemia-market
https://www.delveinsight.com/report-store/hepatorenal-syndrome-market
https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market
https://www.delveinsight.com/report-store/von-hippel-lindau-disease-market
https://www.delveinsight.com/report-store/venous-thromboembolism-market
https://www.delveinsight.com/report-store/urea-cycle-disorders-market
https://www.delveinsight.com/report-store/tendonitis-market
https://www.delveinsight.com/report-store/tendinopathy-market
https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market
https://www.delveinsight.com/report-store/synovial-sarcoma-market
https://www.delveinsight.com/report-store/smoking-cessation-market
https://www.delveinsight.com/report-store/myopia-progression-market
https://www.delveinsight.com/report-store/herpes-zoster-market
https://www.delveinsight.com/report-store/diabetic-nephropathy-market
https://www.delveinsight.com/report-store/geographic-atrophy-ga-market
https://www.delveinsight.com/report-store/carbapenem-resistant-enterobacteriaceae-infection-market
https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
https://www.delveinsight.com/report-store/alpha-thalassemia-market
https://www.delveinsight.com/report-store/biliary-atresia-market
https://www.delveinsight.com/report-store/celiac-disease-cd-market
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
https://www.delveinsight.com/report-store/chronic-venous-ulceration-market
https://www.delveinsight.com/report-store/familial-adenomatous-polyposis-market
https://www.delveinsight.com/report-store/farbers-disease-market
https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
https://www.delveinsight.com/report-store/radiotherapy-induced-oral-mucositis-market
https://www.delveinsight.com/report-store/radiation-dermatitis-market
https://www.delveinsight.com/report-store/polymyalgia-rheumatica-market
https://www.delveinsight.com/report-store/peripheral-nerve-injuries-market
https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size
https://www.delveinsight.com/report-store/type-1-diabetes-market
https://www.delveinsight.com/report-store/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market
https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-market
https://www.delveinsight.com/report-store/radiation-induced-esophagitis-market-forecast
https://www.delveinsight.com/report-store/parainfluenza-virus-infection-market
https://www.delveinsight.com/report-store/ocular-hypertension-market
https://www.delveinsight.com/report-store/heavy-metal-poisoning-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tendinopathy Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 5+ Companies are working to improve the Treatment of Space | MiMedx, Hisamitsu Pharmaceuticals, Seikagaku Corporation here
News-ID: 3281579 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Tendinopathy
Tendinopathy Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tendinopathy pipeline constitutes 5+ key companies continuously working towards developing 5+ Tendinopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Tendinopathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tendinopathy Market.
The Tendinopathy Pipeline report embraces in-depth…
Tendinopathy Market Outlook: Growth Driven by Sports Injuries, Biologics & Advan …
The Global Tendinopathy Market reached US$ 215.26 billion in 2023 and is expected to reach US$ 299.16 billion by 2031 growing with a CAGR of 4.2% during the forecast period 2024-2031.
The tendinopathy market focuses on the diagnosis, treatment, and management of tendinopathy, a condition characterized by pain, swelling, and impaired tendon function caused by overuse, injury, or degeneration. Common types include Achilles, rotator cuff, patellar, and lateral epicondylitis…
Tendinopathy Market Size, Share and Competitive Landscape
Tendinopathy refers to the condition where the tendons, which are the thick fibrous tissues that connect muscles to bones, become damaged or inflamed, leading to pain, swelling, and restricted movement. It is a common issue for athletes, manual laborers, and aging populations. The tendinopathy market is growing rapidly, driven by the rising incidence of sports injuries, increasing healthcare access, and advancements in treatments, including biologics, physical therapy, and surgical interventions.…
Tendinopathy Market is expected to reach US$ 299.16 billion by 2031- Zimmer Biom …
The Tendinopathy Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/tendinopathy-market
What is the projected growth…
Tendinopathy Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, E …
(Albany, USA) The Tendinopathy market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as MiMedx Group, Novartis Pharmaceuticals, Ipsen, Orthocell Limited, ZARS Pharma Inc., Zimmer Biomet, Causeway Therapeutics, Travanti Pharma Inc., Abbisko Therapeutics Co, Ltd, Deciphera Pharmaceuticals, LLC, Daiichi Sankyo, AmMax Bio, Inc., AmMax Bio, Inc.,
DelveInsight's "Tendinopathy Market Insights, Epidemiology, and Market Forecast 2034."…
Tendinopathy Market Forecasted for Substantial Growth (2024-2031) | Zimmer Biome …
The Tendinopathy Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Get a Free Sample PDF - https://datamintelligence.com/download-sample/tendinopathy-market
What is the projected growth rate (CAGR) of the Global Tendinopathy market from 2024…
